QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

20,995 signal articles · 492 in last 24h · 103,318 total before filter · latest 1h ago
492last 24h
2476last 7d
479● bullish (7d)
251● bearish (7d)
197publishers
AllMacro242Earnings1457M&A138Regulatory16Product4Analyst29
✕ clear all filterssentiment: bearishSentiment:bullishneutralbearishshow all (incl. clickbait)
SpaceX Stock Slumps on Massive Spending
The Wall Street Journal5h agobearish
SpaceX Stock Slumps on Massive Spending

Shares of SpaceX slumped more than 10% premarket to around $111 this morning, even after the rocket company reported a 92% surge in quarterly revenue. Investors were spooked by the company’s $18.4 billion in capital expenditure in the second quarter alone, which compared with just $2.8 billion in the prior year. “The concern for investors is how fast expenditure growth is outpacing revenue growth,” said Kathleen Brooks, research director at brokerage XTB.

Bloomberg5h agobearish
Circle Revenue Misses Estimates as Crypto Markets Mired in Rout

(Bloomberg) -- Circle Internet Group Inc. reported second-quarter revenue that missed Wall Street expectations after circulation of its stablecoin USDC fell from a peak amid a protracted slide in cryptocurrency markets. Most Read from BloombergTrump Says Iran Talks Going Well as Hopes Rise for Hormuz DealChina’s AI Blitz Creates ‘Death Zone’ for Rival US Model MakersBeer Dynasty Families Sell €731 Million Stake in AB InBevTaco Bell Met With Michigan on Parasite Weeks Before RecallSpaceX’s AI Spl

AMD falls as investors seek bigger AI payoff
Reuters6h agobearish
AMD falls as investors seek bigger AI payoff

Advanced Micro Devices shares declined before the bell on Wednesday as the chipmaker's stronger-than-expected revenue forecast ‌fell short of lofty expectations and investors sought clearer ‌signs that a multibillion-dollar AI spending boom will translate into faster growth. The move underscores elevated expectations facing AMD as it aims to challenge Nvidia's dominance amid intensifying competition with Intel racing to ‌regain technology leadership after ⁠strong results. "We suspect expectations had moved higher following Intel's results a couple of weeks ago, and the ⁠buyside already has a fairly bullish outlook," said Stacy Rasgon, analyst at Bernstein.

AMD falls as investors seek bigger AI payoff
Reuters6h agobearish
AMD falls as investors seek bigger AI payoff

Advanced Micro Devices shares declined before the bell on Wednesday as the chipmaker's stronger-than-expected revenue forecast ‌fell short of lofty expectations and investors sought clearer ‌signs that a multibillion-dollar AI spending boom will translate into faster growth. The move underscores elevated expectations facing AMD as it aims to challenge Nvidia's dominance amid intensifying competition with Intel racing to ‌regain technology leadership after ⁠strong results. "We suspect expectations had moved higher following Intel’s results a couple of weeks ago, and the ⁠buyside already has a fairly bullish outlook," said Stacy Rasgon, analyst at Bernstein.

Microsoft is Soaring After Earnings While Meta Platforms Drops. Is The Market Giving Zuckerberg Too Little Credit?
24/7 Wall St.16h agobearishVIDEO
Microsoft is Soaring After Earnings While Meta Platforms Drops. Is The Market Giving Zuckerberg Too Little Credit?

On the latest episode of the AI Investor Podcast, 24/7 Wall St. Analyst Austin Smith opens with a puzzle: two companies are being treated in opposite ways for the same underlying behavior. Microsoft is up roughly 16% after Azure growth accelerated from 38% to 43%, with guidance pointing to 45–46%, vindicating a capex program the market had criticized. Meta, meanwhile, is down about 10% at roughly 20x earnings despite 28% top-line growth — and is being punished for the same infrastructure spending, even after Zuckerberg argued that Meta rents out compute at a markup over its cost. Co-host Eric Bleeker's answer is that both moves are likely overreactions, and that the real variable is what each company said versus what Wall Street wanted to hear. Microsoft delivered on message: Azure at a $124 billion run rate, 90% of cloud demand coming from outside the frontier labs, and no capex increase. He frames Microsoft's position as a prisoner's dilemma, since compute routed to Azure is compute unavailable for its own AI products, and argues Microsoft CEO Satya Nadella relented under pressure from prior quarters. He compares the market's discomfort with capex growth to Apple's mid-decade smartphone choppiness versus Google's steadier trajectory. Meta hit every wrong note: an EPS miss on one-time costs, decelerating guidance, Zuckerberg walking back the cloud-capacity revenue opportunity, and incremental compute directed toward Meta Superintelligence rather than the core ad business. Eric estimates the justified moves were only a few percent in either direction, with the rest attributable to PR and positioning. He credits Microsoft's software exposure as valuable diversification, but concludes the share-price gap doesn't reflect any real difference in business trajectory.

Chipotle stock plunges due to salmonella concerns: AlphaSpace check
Yahoo Finance Video19h agobearishVIDEO
Chipotle stock plunges due to salmonella concerns: AlphaSpace check

Yahoo Finance Senior Reporter Brooke DiPalma and Market Domination host Josh Lipton take a closer look at one of Tuesday's trending stories: Chipotle (CMG) pulling its jalapeños due to salmonella concerns. Watch the video above to learn more. Yahoo Finance's AlphaSpace is a premium investment platform that combines data, charting, news, analysis, and more to help retail investors understand markets.

Novo Nordisk Stock Drops on Wegovy Shortfall
The Wall Street Journal20h agobearish
Novo Nordisk Stock Drops on Wegovy Shortfall

U.S.-traded shares of Novo Nordisk are down more than 6% due to a sales shortfall for its new Wegovy weight-loss pill and a disappointing study outcome for a next-generation weight-loss drug. Overall, the company sees the potential for a full-year sales decline of up to 6%, better than its previous view that sales could drop up to 12%. Novo also disclosed that its experimental drug CagriSema failed to show comparable blood-sugar reduction to Eli Lilly’s tirzepatide in a new study of people with Type 2 diabetes.

Deutsche Bank sees jarring signs in Roblox as stock crashes
TheStreet22h agobearish
Deutsche Bank sees jarring signs in Roblox as stock crashes

Roblox (RBLX) stock fell hard over the past year, but its user base kept growing, and plenty of investors were willing to wait for a turnaround. That patience ran out on July 31. Roblox reported second-quarter results, then told the market something concerning. The company expects its ...